Latest News and Press Releases
Want to stay updated on the latest news?
-
Alumis reports third quarter 2025 financial results and highlights recent progress and anticipated milestones including Phase 3 data in early 1Q 2026
-
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
-
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
-
Alumis Stockholders Approve Merger with ACELYRIN
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
-
Alumis to Present at Leerink's 2025 Global Healthcare Conference
-
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
-
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
-
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases